A novel anti-ischemic stroke candidate drug AAPB with dual effects of neuroprotection and cerebral blood flow improvement

Bibliographic Details
Title: A novel anti-ischemic stroke candidate drug AAPB with dual effects of neuroprotection and cerebral blood flow improvement
Authors: Jianbing Wu, Duorui Ji, Weijie Jiao, Jian Jia, Jiayi Zhu, Taijun Hang, Xijing Chen, Yang Ding, Yuwen Xu, Xinglong Chang, Liang Li, Qiu Liu, Yumei Cao, Yan Zhong, Xia Sun, Qingming Guo, Tuanjie Wang, Zhenzhong Wang, Ya Ling, Wei Xiao, Zhangjian Huang, Yihua Zhang
Source: Acta Pharmaceutica Sinica B, Vol 15, Iss 2, Pp 1070-1083 (2025)
Publisher Information: Elsevier, 2025.
Publication Year: 2025
Collection: LCC:Therapeutics. Pharmacology
Subject Terms: Ischemic stroke, Nitric oxide, AAPB, Neuroprotection, Blood flow improvement, Dual effects, Therapeutics. Pharmacology, RM1-950
More Details: Ischemic stroke (IS) is a globally life-threatening disease. Presently, few therapeutic medicines are available for treating IS, and rt-PA is the only drug approved by the US Food and Drug Administration (FDA) in the US. In fact, many agents showing excellent neuroprotection but no blood flow-improving activity in animals have not achieved ideal clinical efficacy, while thrombolytic drugs only improving blood flow without neuroprotection have limited their wider application. To address these challenges and meet the huge unmet clinical need, we have designed and identified a novel compound AAPB with dual effects of neuroprotection and cerebral blood flow improvement. AAPB significantly reduced cerebral infarction and neural function deficit in tMCAO rats, pMCAO rats, and IS rhesus monkeys, as well as displayed exceptional safety profiles and excellent pharmacokinetic properties in rats and dogs. AAPB has now entered phase I of clinical trials fighting IS in China.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2211-3835
Relation: http://www.sciencedirect.com/science/article/pii/S2211383525000048; https://doaj.org/toc/2211-3835
DOI: 10.1016/j.apsb.2024.12.042
Access URL: https://doaj.org/article/e0e2fb65bb9d4aa1a5b437207d73022b
Accession Number: edsdoj.0e2fb65bb9d4aa1a5b437207d73022b
Database: Directory of Open Access Journals
More Details
ISSN:22113835
DOI:10.1016/j.apsb.2024.12.042
Published in:Acta Pharmaceutica Sinica B
Language:English